Eli Lilly and Co., US5324571083

Eli Lilly and Co. stock gains 3.51 percent ahead of the open

Published on 09/25/2026 at 06:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

At the close on September 24, 2026, Eli Lilly and Co. stock rose 3.51 percent to USD 1,191.40. The session range was USD 1,151.00 to USD 1,197.79, while the S&P 500 slipped less than 0.1 percent.

Fotorealistischer Blick auf eine generische Plasma-Etch-Maschine mit lila Plasmaschein durch das Sichtfenster im Halbleiter-Reinraum
Lam Research US5324571083 generische Plasma Etch Maschine mit lila Plasma im modernen Reinraum sichtbar, Illustration mit AI erstellt.

Eli Lilly and Co. stock closed at USD 1,191.40 on the NYSE on September 24, 2026, gaining 3.51 percent. The move outpaced the S&P 500, which fell 1.90 points, or less than 0.1 percent, to 7,704.13 in the same session.

September 24, 2026 in numbers

Eli Lilly and Company (ISIN US5324571083, NYSE: LLY) traded between USD 1,151.00 and USD 1,197.79 on September 24, 2026. Volume reached 2,404,559 shares, compared with an average daily volume of 3,013,247 shares, according to MarketBeat data.

The session followed a previous close of USD 1,150.99. As Lilly announced on September 24, 2026, the FDA approved Onswik, a once-weekly basal insulin for adults with type 2 diabetes. The release said the Phase 3 program involved more than 3,400 adults.

September 25, 2026 outlook

Trading begins ahead of the US session after the FDA approval and the InnoCare research and licensing agreement helped frame the prior session. CNBC reported that the agreement could be worth up to USD 3.35 billion in development and commercial milestones.

Market attention also includes the final September University of Michigan consumer sentiment reading, scheduled for 10:00 a.m. ET on September 25, 2026. The release is a broader market item rather than a company-specific announcement.

Disclaimer...

en | US5324571083 | ELI LILLY AND CO. | boerse | 70181138 | bgmi